Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 19, Pages 4869
Publisher
MDPI AG
Online
2021-09-29
DOI
10.3390/cancers13194869
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis
- (2020) Anouk E. J. Latenstein et al. ACTA ONCOLOGICA
- Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: Preliminary experience
- (2020) Remy Klaassen et al. Molecular Oncology
- Diffusion Kurtosis Imaging—A Superior Approach to Assess Tumor–Stroma Ratio in Pancreatic Ductal Adenocarcinoma
- (2020) Philipp Mayer et al. Cancers
- 1526P First and second-line palliative systemic treatment outcomes in a real-world metastatic pancreatic cancer cohort
- (2020) E. Pijnappel et al. ANNALS OF ONCOLOGY
- Chemotherapy response of pancreatic cancer by diffusion-weighted imaging (DWI) and intravoxel incoherent motion DWI (IVIM-DWI) in an orthotopic mouse model
- (2019) Li Wu et al. MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
- (2019) Andrea Wang-Gillam et al. EUROPEAN JOURNAL OF CANCER
- Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
- (2019) Naoki Mita et al. Journal of Clinical Medicine
- Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients
- (2018) Remy Klaassen et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Repeatability and correlations of dynamic contrast enhanced and T2* MRI in patients with advanced pancreatic ductal adenocarcinoma
- (2018) Remy Klaassen et al. MAGNETIC RESONANCE IMAGING
- Comparison of six fit algorithms for the intra-voxel incoherent motion model of diffusion-weighted magnetic resonance imaging data of pancreatic cancer patients
- (2018) Oliver J. Gurney-Champion et al. PLoS One
- Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
- (2018) Andrew McGuigan et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis
- (2017) Xiu-Wei Zhang et al. Targeted Oncology
- Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis
- (2017) Elie El Rassy et al. Clinics and Research in Hepatology and Gastroenterology
- Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions
- (2017) Aurélien Lambert et al. Therapeutic Advances in Gastroenterology
- Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
- (2016) Hironobu Minami et al. CANCER SCIENCE
- Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer
- (2016) Irina Heid et al. CLINICAL CANCER RESEARCH
- Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature
- (2016) Chiara Caparello et al. Future Oncology
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
- (2016) Sharlene Gill et al. JOURNAL OF CLINICAL ONCOLOGY
- Diffusion MRI in early cancer therapeutic response assessment
- (2016) C. J. Galbán et al. NMR IN BIOMEDICINE
- A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma
- (2016) Andrew H. Ko et al. PANCREAS
- Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
- (2015) Alix Portal et al. BRITISH JOURNAL OF CANCER
- The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal
- (2015) Maarten F. Bijlsma et al. CANCER AND METASTASIS REVIEWS
- Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
- (2015) Daniel V.T. Catenacci et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
- (2015) Michael R Migden et al. LANCET ONCOLOGY
- A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
- (2014) J. Rodon et al. CLINICAL CANCER RESEARCH
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: Correlation with histological microvessel density
- (2013) Hye-Jeong Lee et al. MAGNETIC RESONANCE IN MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Pancreas Cancer Microenvironment
- (2012) C. Feig et al. CLINICAL CANCER RESEARCH
- Tumour response prediction by diffusion-weighted MR imaging: Ready for clinical use?
- (2012) Linda Heijmen et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance
- (2012) Mert Erkan et al. CURRENT MOLECULAR MEDICINE
- 3D Slicer as an image computing platform for the Quantitative Imaging Network
- (2012) Andriy Fedorov et al. MAGNETIC RESONANCE IMAGING
- FOLFIRINOX: A Small Step or a Great Leap Forward?
- (2011) Andrew H. Ko JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic cancer stem cells: A new target for anti-cancer therapy?
- (2010) Patrick C. Hermann et al. CELL CYCLE
- Predicting and monitoring cancer treatment response with diffusion-weighted MRI
- (2010) Harriet C. Thoeny et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
- The Hedgehog Pathway and Pancreatic Cancer
- (2009) Manuel Hidalgo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation